Identification of G-Quadruplex Inducers Usinga Simple, Inexpensiveand Rapid High Throughput Assay, and TheirInhibition of Human Telomerase

Open Medicinal Chemistry Journal

Volumn 6, Issue 1, 2012, Pages 20-28

  Sassano, Maria Florencia ^a   Schlesinger, Alexander P ^a   Jarstfer, Michael B ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Ellipticine; Furamidine; G quadruplex; Telomerase; Telomere

Indexed keywords

DNA; DNA POLYMERASE; GUANINE QUADRUPLEX; NSC 12155; NSC 13013; NSC 130813; NSC 17600; NSC 176327; NSC 305831; NSC 35489; NSC 354961; NSC 357777; NSC 638432; NSC 95609; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DNA BINDING; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; STOICHIOMETRY; VALIDATION PROCESS;

EID: 84870975565     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501206010020     Document Type: Article

References (45)

1. Blasco, M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet., 2005, 6, 611-622.
2. de Lange, T. Protection of mammalian telomeres. Oncogene., 2002, 21, 532-540.
3. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 2005, 19, 2100-2110.
4. Neidle, S.; Parkinson G.N. The structure of telomeric DNA. Curr. Opin. Struct. Biol., 2003, 13, 275-283.
5. Bryan, T.M.; Cech, T.R. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol., 1999, 11, 318-324.
6. Cech, T.R.; Lingner, J. Telomerase and the chromosome end replication problem. Ciba Found Symp., 1997, 211, 20-8; discussion 28-34.
7. Cech, T.R. Life at the end of the Chromosome: telomeres and telomerase. Angew. Chem. Int. Ed. Engl., 2000, 39, 34-43.
8. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
9. Rezler, E.M., Bearss, D.J.; Hurley, L.H. Telomere inhibition and telomere disruption as processes for drug targeting. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 359-379.
10. Neidle, S.; Parkinson G. Telomere maintenance as a target for anticancer drug discovery. Nat. Rev. Drug Discov., 2002. 1, 383-393.
11. Folini, M.; Gandellini, P.; Zaffaroni, N. Targeting the telosome: therapeutic implications Biochim. Biophys. Acta, 2009, 1792, 309-316.
12. Harley, C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer, 2008, 8, 167-179.
13. Burge, S.; Parkinson, G. N; Hazel, P.; Todd, A.K.; Neidle, S. Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res., 2006, 34, 5402-5415.
14. Monchaud, D.; Teulade-Fichou, M.P. A hitchhiker's guide to Gquadruplex ligands. Org. Biomol. Chem., 2008, 6, 627-636.
15. Todd, A.K.; Johnston, M.; Neidle, S. Highly prevalent putative quadruplex sequence motifs in human DNA. Nucleic Acids Res., 2005, 33, 2901-207.
16. Huppert, J.L.; Balasubramanian, S. G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res., 2007, 35, 406-413.
17. Oganesian, L. and T.M. Bryan Physiological relevance of telomeric G-quadruplex formation: a potential drug target. Bioessays., 2007, 29, 155-165.
18. Pagano, B.; Giancola, C. Energetics of quadruplex-drug recognition in anticancer therapy. Curr. Cancer. Drug. Targets., 2007, 7, 520-540.
19. Zahler, A.M., Williamson, J.R.; Cech, T.R.; Prescott, D.M. Inhibition of telomerase by G-quartet DNA structures. Nature, 1991, 350, 718-720.
20. Salvati, E.; Leonetti, C.; Rizzo, A.; Scarsella, M.; Mottolese, M.; Galati, R.; Sperduti, I.; Stevens, M.F.; D'Incalci, M.; Blasco, M.; Chiorino, G.; Bauwens, S.; Horard, B.; Gilson, E.; Stoppacciaro, A.; Zupi, G.; Biroccio, A. Telomere damage induced by the Gquadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest., 2007, 117, 3236-3247.
21. Fu, Y.T.; Keppler, BR.; Soares, J.; Jarstfer, M.B. BRACO19 analog dimers with improved inhibition of telomerase and hPot 1. Bioorg. Med. Chem., 2009,17, 2030-2037.
22. Gomez, D.; O'Donohue, M.F.; Wenner, T.; Douarre, C.; Macadre, J.; Koebel, P.; Giraud-Panis, M.J.; Kaplan, H.; Kolkes, A.; Shin-ya, K.; Riou. J.F. The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. Cancer Res., 2006, 66, 6908-6912.
23. Xu, Y. Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA. Chem. Soc. Rev., 2011. 40, 2719-2740.
24. Burger, A.M.; Dai, F.; Schultes, C.M.; Reszka, A.P.; Moore, M.J.; Double, J.A.; Neidle, S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res., 2005, 65, 1489-1496.
25. Gowan, S.M.; Harrison, J.R.; Patterson, L.; Valenti, M.; Read, M.A.; Neidle, S.; Kelland, L.R. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol., 2002,61, 1154-1162.
26. Taetz, S.; Baldes, C.; Murdter, T.E.; Kleideiter, E.; Piotrowska, K.; Bock, U.; Haltner-Ukomadu, E.; Mueller, J.; Huwer, H.; Schaefer, U.F.; Klotz, U.; Lehr, C.M. Biopharmaceutical characterization of the telomerase inhibitor BRACO19. Pharm. Res., 2006, 23, 1031-1037.
27. Drygin, D.; Siddiqui-Jain, A.; O'Brien, S.; Schwaebe, M.; Lin, A.; Bliesath, J.;. Ho, C. B; Proffitt, C.; Trent, K.; Whitten, J.P.; Lim, J.K.; Von Hoff, D.; Anderes, K.; Rice, W.G. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res., 2009, 69, 7653-7661.
28. Mergny, J.L.; Lacroix, L.; Teulade-Fichou, M.P.; Hounsou, C.; Guittat, L.; Hoarau, M.; Arimondo, P.B.; Vigneron, J.P.; Lehn, J.M.; Riou, J.F.; Garestier, T.; Helene, C. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 3062-3067.
29. Collie, G.W.; Parkinson, G.N. The application of DNA and RNA G-quadruplexes to therapeutic medicines. Chem. Soc. Rev., 2011,40, 5867-5892.
30. Ueyama, H.; Takagi, M.; Takenaka, S. A novel potassium sensing in aqueous media with a synthetic oligonucleotide derivative. Fluorescence resonance energy transfer associated with Guanine quartet-potassium ion complex formation. J. Am. Chem. Soc., 2002, 124, 14286-14287.
31. Brown, R.V.; Danford, F.L.; Gokhale, V.; Hurley, L.H.; Brooks, T.A. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J. Biol. Chem., 2011, 286, 41018-41027.
32. Pitts, A.E.; Corey, D.R. Inhibition of human telomerase by 2'-Omethyl-RNA. Proc. Natl. Acad. Sci. USA., 1998, 95, 11549-11554.
33. Han, H.; Hurley, L.H.; Salazar, M. A DNA polymerase stop assay for G-quadruplex-interactive compounds. Nucleic Acids Res., 1999, 27, 537-542.
34. Rezler, E.M.; Seenisamy, J.; Bashyam, S.; Kim, M.Y.; White, E.; Wilson, W.D.; Hurley, L.H. Telomestatin and diseleno sapphyrin bind selectively to two different forms of the human telomeric Gquadruplex structure. J. Am. Chem. Soc., 2005,127, 9439-9447.
35. White, E.W.; Tanious, F.; Ismail, M.A.; Reszka, A.P.; Neidle, S.; Boykin, D.W.; Wilson, W.D. Structure-specific recognition of quadruplex DNA by organic cations: influence of shape, substituents and charge. Biophys. Chem., 2007, 126, 140-153.
36. Garbett, N.C.; Ragazzon, P.A.; Chaires, J.B. Circular dichroism to determine binding mode and affinity of ligand-DNA interactions. Nat. Protoc., 2007, 2, 3166-3172.
37. Keniry, M.A. Quadruplex structures in nucleic acids. Biopolymers., 2001, 56, 123-146.
38. Antony, S.; Marchand, C.; Stephen, A.G.; Thibaut, L.; Agama, K.K.; Fisher, R.J.; Pommier, Y. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res., 2007, 35, 4474-4484.
39. Reha, D.; Kabelac, M.; Ryjacek, F.; Sponer, J.; Sponer, J.E.; Elstner, M.; Suhai, S.; Hobza, P. Intercalators. 1. Nature of stacking interactions between intercalators (ethidium, daunomycin, ellipticine, and 4',6-diaminide-2-phenylindole) and DNA base pairs. Ab initio quantum chemical, density functional theory, and empirical potential study. J. Am. Chem. Soc., 2002, 124, 3366-3376.
40. Bertrand, J.R.; Giacomoni, P.U. Ellipticines: correlation between in vitro DNA intercalation and physiological properties? Chemioterapia., 1985, 4, 445-453.
41. Delbarre, A.; Oberlin, R.; Roques, B.P.; Borgna, J.L.; Rochefort, H.; J Le Pecq,.B.; Jacquemin-Sablon, A. Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer. J. Med. Chem., 1985, 28, 752-761.
42. Pommier, Y.; Schwartz, R.E.; Zwelling, L.A.;. Kohn, K.W. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry., 1985, 24, 6406-6410.
43. Garbett, N.C.; Graves, D.E. Extending nature's leads: the anticancer agent ellipticine. Curr. Med. Chem. Anticancer Agents., 2004, 4, 149-172.
44. Cristofari, G.; Reichenbach, P.; Regamey, P.O.; Banfi, D.; Chambon, M.; Turcatti, G.; Lingner, J. Low-to high-throughput analysis of telomerase modulators with Telospot. Nat. Methods., 2007, 4, 851-853.
45. Keppler, B.R.; Jarstfer, M.B. Inhibition of telomerase activity by preventing proper assemblage. Biochemistry., 2004, 43, 334-343.